RE:Drug cost a key factor to oncologistsScienceFirst wrote: Another thing in our favor. Our only 2-doses treatment should give us enough of room to displace competition on the price aspect.
Gene therapy like Ferring's recently approved Adstiladrin will be harder to sell because it price tag will be high.
US oncologists see cost as biggest barrier to new cancer drug uptake, with cell, gene therapy expertise lagging: survey
https://www.fiercepharma.com/marketing/us-oncologists-see-cost-biggest-barrier-new-cancer-drug-uptake-cell-gene-therapy
Oncologists in the U.S. see pricing as the largest hurdle for patients when it comes to accessing new cancer therapies, while many are also struggling to keep up with the pace of new cell and gene therapies.
That’s according to a new survey out this month from healthcare research firm Sermo, which surveyed more than 300 oncologists.
Great post ScienceFirst. Insurance companies will absolutely play a major role in Theralase's treatment as well as doctors pushing the direction of patients toward the less expensive and better performer in the fight against NMIBC. With more awareness of this treatment spreading through the medical community the larger the revenue stream for TLT and less cost to both Hospitals & Insurance companies. Hospitals will have more available bed space as patients are able to go home rather than be under their care, notably a stress reliever for doctors & nurses.